First patient dosed in Neuren PMS Phase 3 trial
- Date and time
- Announcement type
- Company Update
Show detailsHide details
- Category
- Other
- Report codes
- 11001
- Sector
- Health Care
- Industry group
- Pharmaceuticals, Biotechnology & Life Sciences
Recent NEU announcements
- Neuren H1 2026 Financial Results Webinar on 26 August 2026
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- Neuren highlights participation in PMSF Family Conference
- DAYBU recommended for approval in the European Union
- Application for quotation of securities - NEU
- Notification of cessation of securities - NEU